CELLULOSE-SYNTHASE-LIKE ENZYMES AND USES THEREOF

    公开(公告)号:US20220217934A1

    公开(公告)日:2022-07-14

    申请号:US17272685

    申请日:2019-09-05

    IPC分类号: A01H6/82 C12N15/82 C12N9/10

    摘要: Provided herein are genetically modified cells and genetically modified plants having increased or decreased expression of a cellulose synthase like G (CSLG) enzyme. These cells and plants may have an increased or decreased content a steroidal alkaloid, a steroidal saponin, or a triterpenoid saponin, compared to a corresponding unmodified cell or plant. Also provided herein are methods of producing a steroidal alkaloid, a steroidal saponin, or a triterpenoid saponin in a genetically modified cell, as well as methods of reducing the content of a steroidal alkaloid, a steroidal saponin, or a triterpenoid saponin in a cell of a plant or a plant part, and methods of increasing the content of a steroidal alkaloid, a steroidal saponin, or a triterpenoid saponin in a cell of a plant or a plant part.

    METHODS OF TREATING PAIN
    37.
    发明申请

    公开(公告)号:US20220133701A1

    公开(公告)日:2022-05-05

    申请号:US17576954

    申请日:2022-01-16

    摘要: Methods of treating pain are provided. Accordingly, there is provided a method of treating nociceptive or neuropathic pain in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an agent which binds importin alpha3 or a polynucleotide encoding same and inhibits expression and/or activity of said importin α3.

    METHODS OF TREATING MOTOR NEURON DISEASES

    公开(公告)号:US20210369761A1

    公开(公告)日:2021-12-02

    申请号:US17391125

    申请日:2021-08-02

    摘要: A method of treating a subject having MND is provided. The method comprising administering to the subject a therapeutically effective amount of an agent selected from the group consisting of miR-218, miR-218*, precursor thereof and a polynucleotide sequence encoding miR-218 or miR-218* or precursor thereof, thereby treating the MND in the subject. A method of treating a subject having MND, the method comprising administering to the subject a therapeutically effective amount of an agent capable of downregulating an activity or expression of a gene product selected from the group consisting of KCND2, KCNH1, GABRB2, SLC6A1, SLC6A11, KCNA1, CACNB4, GRIA2, GRIK2, GABRG1 and GRIK3, is also provided.